How to lose fat on Ozempic or Wegovy
On this page
Ozempic and Wegovy are the same drug, semaglutide. Wegovy is the version approved for weight loss, and Ozempic is approved for type 2 diabetes. In the main weight loss trial, 1,961 adults on a weekly 2.4 mg shot lost 14.9% of their weight in 68 weeks, against 2.4% on placebo. To make that loss mostly fat, eat protein first, lift weights and keep the habits when you stop.
What we’d do
Let the drug handle the hunger and put your effort into what the loss is made of. Eat protein first at every meal, even when you’re not hungry, and don’t fall under the typical range (find yours). Lift two or three days a week, or three as the US advisory suggests. Walk daily, weigh every morning, measure your waist each month and log one lift. If you’re losing very fast or can’t eat enough, tell your prescriber. Every dose decision is theirs.
If you remember three things
- The average loss was about 15% in a year and a half, and half of people lost 15% or more.
- Up to about 40% of the loss in its scan study was lean mass. Protein and lifting are how you keep more muscle.
- Two thirds came back within a year of stopping in the trial. Build the habits while you’re on it.
Ozempic or Wegovy: what’s the difference?
| Wegovy | Ozempic | |
|---|---|---|
| Approved for | Weight loss in adults and teens 12 and older, and lowering heart risk | Type 2 diabetes |
| How it’s taken | Weekly shot, or a daily pill approved in December 2025 | Weekly shot |
| Usual top dose | 2.4 mg a week for the shot | 2 mg a week |
| FDA approval for weight | June 2021 | Not approved for weight loss |
The drug inside is the same. The doses and the approvals differ, and your prescriber chooses.
How semaglutide works
Semaglutide copies GLP-1, a hormone your gut releases when you eat. It acts on the parts of your brain that control appetite, so you feel less hungry and full sooner, and it slows how fast your stomach empties. It stays in the blood about a week, which is why it’s a weekly shot, and it takes five to seven weeks to leave your body after the last dose.
The drug is like a strong tailwind. It moves you faster, and you still do the steering.

What the trials found
The main weight loss trial
1,961 adults with obesity or overweight, 68 weeks. STEP 1, NEJM, 2021
14.9% of body weight lost on semaglutide against 2.4% on placebo, about 34 pounds (15.3 kg) against 6 (2.6 kg). 86% lost at least 5%, 69% at least 10% and 51% at least 15%.
Everyone also got diet and activity advice.
Against the daily drug
338 adults, 68 weeks. STEP 8, JAMA, 2022
15.8% lost on weekly semaglutide against 6.4% on daily liraglutide (Saxenda).
Open label: people knew which drug they took.
Against tirzepatide
751 adults, 72 weeks. SURMOUNT-5, NEJM, 2025
13.7% lost on semaglutide against 20.2% on tirzepatide (Zepbound).
Open label, highest tolerated dose of each.
The heart
17,604 adults with heart disease and overweight, no diabetes. SELECT, NEJM, 2023
20% fewer heart attacks, strokes and heart deaths on semaglutide than placebo over about 40 months.
More people stopped the drug for side effects: 16.6% against 8.2%.
How much of the loss is muscle?
In STEP 1, 140 people had DEXA scans. On semaglutide their fat mass fell 19.3%, their deep belly fat 27.4% and their lean mass 9.7%. Of the weight lost, the 2025 US nutrition advisory counts about 62% as fat and 38% as lean mass. Lean mass includes water and organs, so muscle is only part of it.
A 2026 study is more hopeful. In SEMALEAN, 106 adults with severe obesity took semaglutide for a year. Their lean mass fell about 7 pounds (3 kg) by month seven and then held steady, and their grip strength rose by about 9 pounds (4 kg).
How to keep muscle on it
- Protein first. Make every meal, however small, start with protein: eggs, Greek yogurt, fish, chicken, tofu, a protein shake.
- Lift. The 2025 advisory suggests strength training at least three times a week, plus at least 150 minutes of moderate cardio.
- Watch the pace with your prescriber. In athletes, faster loss kept less lean mass. If you’re losing much more than 1% of your weight a week, bring it up.
- Track a lift and your waist, not only the scale. See am I losing fat or muscle.
What happens when you stop
In the STEP 1 extension, 327 people who stopped semaglutide after 68 weeks had lost 17.3% of their weight. A year later they were only 5.6% below where they started, and most of their health gains had faded. In STEP 4, people switched to a placebo after 20 weeks regained 6.9% over the next 48 weeks, while those who stayed on it lost another 7.9%. More in what happens when you stop taking Ozempic.
The side effects that matter
| Side effect, Wegovy 2.4 mg | Semaglutide | Placebo |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 11% |
| Gallstones | 1.6% | 0.7% |
| Severe stomach reactions | 4.1% | 0.9% |
The label also warns of pancreatitis, low blood sugar when taken with insulin or some diabetes pills, kidney injury from losing fluid, a faster heart rate and allergic reactions. It carries a boxed warning because semaglutide caused thyroid tumors in rodents, so people with a personal or family history of medullary thyroid cancer or MEN 2 shouldn’t take it. Tell your surgeon before any procedure that needs anesthesia. The Wegovy label says it may harm an unborn baby and advises stopping it at least two months before a planned pregnancy, because it lasts so long in the body. Plan that with your doctor.
More detail: doses and the pill
The Wegovy shot starts at 0.25 mg a week and steps up every four weeks to 1.7 or 2.4 mg, and the label now allows a higher 7.2 mg dose after at least four weeks on 2.4 mg. The Wegovy pill is taken once a day and steps up to 25 mg. In its trial, people lost 13.6% of their weight at 64 weeks against 2.4% on placebo. Ozempic goes up to 2 mg a week for diabetes. These are the label’s steps for your prescriber to choose from, never a schedule to follow on your own.
14 sources
- US Food and Drug Administration, Wegovy (semaglutide) prescribing information, DailyMeddailymed.nlm.nih.gov
- US Food and Drug Administration, Ozempic (semaglutide) prescribing information, DailyMeddailymed.nlm.nih.gov
- US Food and Drug Administration, June 2021 Office of Women's Health e-update, FDA approves new drug treatment for chronic weight management, first since 2014fda.gov
- Novo Nordisk, Wegovy pill FDA approval, 2025novonordisk-us.com
- Wilding et al., Once-weekly semaglutide in adults with overweight or obesity (STEP 1), New England Journal of Medicine, 2021pubmed.ncbi.nlm.nih.gov
- Wilding et al., Impact of semaglutide on body composition in adults with overweight or obesity: exploratory analysis of the STEP 1 study, Journal of the Endocrine Society, 2021pmc.ncbi.nlm.nih.gov
- Mozaffarian et al., Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society, American Journal of Clinical Nutrition, 2025pmc.ncbi.nlm.nih.gov
- Alissou et al., Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study, Diabetes, Obesity and Metabolism, 2026pmc.ncbi.nlm.nih.gov
- Wilding et al., Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension, Diabetes, Obesity and Metabolism, 2022pmc.ncbi.nlm.nih.gov
- Rubino et al., Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial, JAMA, 2021pmc.ncbi.nlm.nih.gov
- Rubino et al., Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial, JAMA, 2022pubmed.ncbi.nlm.nih.gov
- Garthe et al., Effect of two different weight-loss rates on body composition and strength and power-related performance in elite athletes, International Journal of Sport Nutrition and Exercise Metabolism, 2011pubmed.ncbi.nlm.nih.gov
- Lincoff et al., Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT), New England Journal of Medicine, 2023pubmed.ncbi.nlm.nih.gov
- Aronne et al., Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5), New England Journal of Medicine, 2025pubmed.ncbi.nlm.nih.gov